Table 1.
Parameters used in the GUIDE algorithm
| Demographics | Clinical characteristics | Biomarkers |
|---|---|---|
| Continuous | ||
| Age | Duration of RA | C x C motif chemokine ligand 13 |
| SJC (28 joints) | CRP | |
| SJC (68 joints) | IL-6 | |
| TJC (28 joints) | MMP3 | |
| TJC (68 joints) | MMP-degraded type 1 collagen | |
| ACR20 at week 24 | MMP-degraded type 3 collagen | |
| DAS28 at baseline | OC | |
| Joint erosion score | OPG | |
| Joint space narrowing score | RANKL | |
| RANKLF | ||
| RANKL: OPG ratio | ||
| RANKLF: OPG ratio | ||
| Soluble glycoprotein 130 | ||
| Soluble intercellular adhesion molecule | ||
| Soluble IL-6 receptor | ||
| Categorical | ||
| Sex | Prior csDMARDs | Anti-CCP (presence or absence) |
| Alcohol use | Number of csDMARDs | Persistent ADAbs |
| BMI stratum | Number of prior bDMARDs | Rheumatoid factor |
| Race | Type of prior bDMARDs | Transient ADAbs |
| Religion | Duration of RA (3-year strata) | Neutralizing anti-drug antibodies |
| Smoking history | Treatment arm code | |
All variables are baseline except ACR20 at week 24
Anti-CCP anti-cyclic citrullinated peptide, ACR20, American College of Rheumatology 20% response, ADAb anti-drug antibody, BMI body mass index, CRP C-reactive protein, bDMARD biological disease-modifying antirheumatic drug; csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28 28-joint disease activity score, IL-6 interleukin-6, MMP matrix metalloproteinase, OC osteocalcin, OPG osteoprotegerin, RA rheumatoid arthritis, RANKL receptor activator of NF-kappa B ligand, RANKLF free RANKL, SJC swollen joint count, TJC tender joint count